Eagle Pharmaceuticals, Inc. (EGRX) Reaches $64.16 After 4.00% Up Move; 5 Analysts Covering Capstone Turbine (CPST)

February 15, 2018 - By Richard Conner

Among 6 analysts covering Capstone Turbine Corporation (NASDAQ:CPST), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Capstone Turbine Corporation had 20 analyst reports since August 7, 2015 according to SRatingsIntel. Roth Capital maintained Capstone Turbine Corporation (NASDAQ:CPST) rating on Friday, October 27. Roth Capital has “Buy” rating and $2.0 target. H.C. Wainwright maintained the shares of CPST in report on Tuesday, July 18 with “Buy” rating. The stock of Capstone Turbine Corporation (NASDAQ:CPST) has “Hold” rating given on Wednesday, June 14 by Oppenheimer. The rating was maintained by H.C. Wainwright on Thursday, August 10 with “Buy”. Craig Hallum downgraded Capstone Turbine Corporation (NASDAQ:CPST) on Friday, October 2 to “Hold” rating. Oppenheimer maintained the stock with “Hold” rating in Wednesday, August 9 report. On Tuesday, September 22 the stock rating was initiated by H.C. Wainwright with “Buy”. The company was maintained on Wednesday, June 14 by H.C. Wainwright. The stock has “Buy” rating by Oppenheimer on Wednesday, October 4. As per Monday, September 18, the company rating was upgraded by Roth Capital. See Capstone Turbine Corporation (NASDAQ:CPST) latest ratings:

27/10/2017 Broker: Roth Capital Rating: Buy New Target: $2.0 Maintain
11/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $2.0 Maintain
04/10/2017 Broker: Oppenheimer Rating: Buy New Target: $2.0 Upgrade
18/09/2017 Broker: Roth Capital Rating: Buy Upgrade

The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is a huge mover today! The stock increased 4.02% or $2.48 during the last trading session, reaching $64.16. About 142,785 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 79.40% since February 15, 2017 and is uptrending. It has outperformed by 62.70% the S&P500.The move comes after 7 months positive chart setup for the $957.37 million company. It was reported on Feb, 15 by Barchart.com. We have $66.73 PT which if reached, will make NASDAQ:EGRX worth $38.29 million more.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma has $119 highest and $37.0 lowest target. $73.50’s average target is 14.56% above currents $64.16 stock price. Eagle Pharma had 21 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Mizuho given on Monday, June 20. The firm earned “Outperform” rating on Tuesday, May 10 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Buy” on Friday, September 1. Mizuho upgraded it to “Buy” rating and $78 target in Thursday, November 3 report. Mizuho initiated Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Wednesday, December 9 with “Buy” rating. The rating was maintained by William Blair with “Outperform” on Wednesday, November 2. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Wednesday, October 26. Mizuho has “Buy” rating and $62 target. The rating was maintained by Piper Jaffray on Wednesday, July 29 with “Overweight”. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Underperform” rating by Mizuho on Monday, January 9. Mizuho maintained it with “Sell” rating and $37.0 target in Monday, December 18 report.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $957.37 million. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 10.28 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on March, 7. They expect $1.19 earnings per share, down 66.19% or $2.33 from last year’s $3.52 per share. EGRX’s profit will be $17.76 million for 13.48 P/E if the $1.19 EPS becomes a reality. After $1.07 actual earnings per share reported by Eagle Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.21% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: